CoChat
Sign Up
Cited by 113Atrial Fibrillation Management and OutcomesHeart Failure Treatment and ManagementCardiac Health and Mental Health

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Digoxin and mortality in atrial fibrillation: a prospective cohort study

Hallberg, Pär, Lindbäck, Johan, Lindahl, Bertil, Stenestrand, Ulf, Melhus, Håkan, for the RIKS-HIA group·2007·European Journal of Clinical Pharmacology
DOI 10.1007/s00228-007-0346-9
Open this paper in CoChat — free account

Abstract

Objective The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study showed that rhythm-control treatment of patients with atrial fibrillation (AF) offered no survival advantage over a rate-control strategy. In a subgroup analysis of that study, it was found that digoxin increased the death rate [relative risk (RR) = 1.42), but it was suggested that this may have been attributable to prescription of digoxin for patients at greater risk of death, such as those with congestive heart failure (CHF). No study has investigated a priori the effect of digoxin on mortality in patients with AF. This study aimed to address this question.Methods Using data from the Registry of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA), we studied the 1-year mortality among patients admitted to coronary care units with AF, CHF, or AF+CHF with or without digoxin (n = 60,764) during 1995-2003. Adjustment for differences in background characteristics and other medications and treatments was made by propensity scoring.Results Twenty percent of patients with AF without CHF in this cohort were discharged with digoxin. This group had a higher mortality rate than the corresponding group not given digoxin [adjusted RR 1.42 (95% CI 1.29-1.56)], whereas no such difference was seen among patients with CHF with or without AF, although these patients had a nearly three-times higher mortality.Conclusion The results suggest that long-term therapy with digoxin is an independent risk factor for death in patients with AF without CHF.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00228-007-0346-9

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 44 references

Cited by

Sorted by citations

Items 101–113 of 113

Related

See all

Metadata

Authors
Hallberg, P., Lindbäck, J., Lindahl, B., Stenestrand, U., Melhus, H., & for the RIKS-HIA group
Affiliations
  • Uppsala University (SE)
  • Linköping University Hospital (SE)
Corresponding author
Hallberg, Pär
ORCID
Venue
European Journal of Clinical Pharmacology
Publisher
Springer Science and Business Media LLC
Published
2007-08-08
Volume
63
Issue
10
Pages
959-971
ISSN
  • 0031-6970 (ISSN-L)
  • 1432-1041
DOI
10.1007/s00228-007-0346-9
OpenAlex
W1967375232
Cited by
113
References
44
Citations by year
2025: 2 · 2024: 2 · 2022: 5 · 2021: 8 · 2020: 7 · 2019: 5 · 2018: 8 · 2017: 4 · 2016: 16 · 2015: 19 · 2014: 10 · 2013: 4 · 2012: 5
FWCI
3.51
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Hjärt-Lungfonden
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords
digoxin, atrial fibrillation, mortality, congestive heart failure, coronary care unit admission, rhythm control, rate control, cardiovascular risk factors
MeSH terms
Aged, Aged, 80 and over, Anti-Arrhythmia Agents, Atrial Fibrillation, Creatinine, Digoxin, Female, Heart Failure, Humans, Male, Myocardial Infarction, Prospective Studies, Registries, Research Design, Risk Factors, Stroke Volume, Sweden, Time Factors, Proportional Hazards Models, Ventricular Function, Left, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review